Dragana Vujic

Prof. Dragana Vujic

Prof

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
ABAna Borojevic
Ana Borojevic
AJAleksandra Jaukovic
Aleksandra Jaukovic
TKTamara Kukolj
Tamara Kukolj
SMSlavko B. Mojsilovic
Slavko B. Mojsilovic
HOHristina Obradović
Hristina Obradović
DBDiana S. Bugarski
Diana S. Bugarski
The biology of vitamin D3 is well defined, as are the effects of its active metabolites on various cells, including mesenchymal stromal/stem cells (MSCs). However, the biological potential of its precursor, cholecalciferol (VD3), has not been sufficiently investigated, although its significance in regenerative medicine—mainly in combination with various biomaterial matrices—has been recognized. Given that VD3 preconditioning might also contribute to the improvement of cellular regenerative potential, the aim of this study was to investigate its effects on bone marrow (BM) MSC functions and the signaling pathways involved. For that purpose, the influence of VD3 on BM-MSCs obtained from young human donors was determined via MTT test, flow cytometric analysis, immunocytochemistry, and qRT-PCR. Our results revealed that VD3, following a 5-day treatment, stimulated proliferation, expression of pluripotency markers (NANOG, SOX2, and Oct4), and osteogenic differentiation potential in BM-MSCs, while it reduced their senescence. Moreover, increased sirtuin 1 (SIRT1) expression was detected upon treatment with VD3, which mediated VD3-promoted osteogenesis and, partially, the stemness features through NANOG and SOX2 upregulation. In contrast, the effects of VD3 on proliferation, Oct4 expression, and senescence were SIRT1-independent. Altogether, these data indicate that VD3 has strong potential to modulate BM-MSCs’ features, partially through SIRT1 signaling, although the precise mechanisms merit further investigation.

Verified
Journal Article
Open access
PDF file
TKTamara Kukolj
Tamara Kukolj
JLJasmina Lazarević
Jasmina Lazarević
ABAna Borojevic
Ana Borojevic
URUroš Ralević
Uroš Ralević
DVDragana Vujic
Dragana Vujic
DBDiana S. Bugarski
Diana S. Bugarski
The heterogeneity of stem cells represents the main challenge in regenerative medicine development. This issue is particularly pronounced when it comes to the use of primary mesenchymal stem/stromal cells (MSCs) due to a lack of identification markers. Considering the need for additional approaches in MSCs characterization, we applied Raman spectroscopy to investigate inter-individual differences between bone marrow MSCs (BM-MSCs). Based on standard biological tests, BM-MSCs of analyzed donors fulfill all conditions for their characterization, while no donor-related specifics were observed in terms of BM-MSCs morphology, phenotype, multilineage differentiation potential, colony-forming capacity, expression of pluripotency-associated markers or proliferative capacity. However, examination of BM-MSCs at a single-cell level by Raman spectroscopy revealed that despite similar biochemical background, fine differences in the Raman spectra of BM-MSCs of each donor can be detected. After extensive principal component analysis (PCA) of Raman spectra, our study revealed the possibility of this method to diversify BM-MSCs populations, whereby the grouping of cell populations was most prominent when cell populations were analyzed in pairs. These results indicate that Raman spectroscopy, as a label-free assay, could have a huge potential in understanding stem cell heterogeneity and sorting cell populations with a similar biochemical background that can be significant for the development of personalized therapy approaches.

1 January 2018 in Vojnosanitetski Pregled
Verified
Journal Article
Open access
OSOlivera Serbic-Nonkovic
Olivera Serbic-Nonkovic
MKMilos Kuzmanovic
Milos Kuzmanovic
MZMaja Zivotic
Maja Zivotic
SZSvetlana Zunic
Svetlana Zunic
DJDragana Jovicic-Gojkov
Dragana Jovicic-Gojkov
DVDragana Vujic
Dragana Vujic
Background/Aim. Transfusion reaction is an adverse event which manifests during or after administration of blood components to the patient. We aimed to show less known aspects of most common transfusion reactions (allergic and febrile non-hemolytic transfusion reactions ? FNHTR) in the pediatric population at the platelet concentrates. The aim of this study was to determine the role of the accumulated cytokines interleukin-6 (IL-6), interlekin- 8 (IL-8) and presence of anti-platelet antibodies in the etiology of transfusion reaction in children. Methods. The study included 239 pediatric patients, who received platelet concentrates. Data of reported transfusion reaction were collected and evaluated prospectively. The levels of IL-6 and IL-8 were determined using an immunoassay. Antihuman leukocyte antigen antibodies (anti-HLA) and antihuman platelet antigen antibodies (anti-HPA) were identified by Luminex flow cytometry. Results. Toral of 70 transfusion reactions were recorded 52 patients. Allergic reactions occurred in most of the cases (74.3%), followed by FNHTR (17.1%). Platelets derived from buffy coat caused the majority of reactions (73.5%). Patients with infection after platelet transfusion with FNHTR had the highest levels of IL-6, 483.30 ? 1,041.79 pg/mL (p = 0.020). Respectively, the febrile patients had IL-6, 302.52 ? 720.04 pg/mL (p = 0.004). The level of IL-8 in platelet units that caused transfusion reactions was 95.66 ? 319.10 pg/mL, which was significantly higher (p = 0.001) compared to the control platelet units. Conclusion. The predominant etiologic mechanism for FNHTR in our study was leukocyte derived cytokine accumulation during storage. Etiopathogenesis of FNHTR induced by IL-6 and IL- 8 presented differently. We concluded that significant factors in the etiology of FNHTR by IL-6 were the factors related to the pediatric patient (infection, inflammation).

27 March 2014
Verified
Book Chapter
Closed access
PDF file
DVDragana Vujic
Dragana Vujic
ELEmilija Lazic
Emilija Lazic
ZZZeljko Zecevic
Zeljko Zecevic
SVSvetlana Vekic
Svetlana Vekic

1 January 2020 in Hrana i ishrana
Verified
Journal Article
Closed access
PDF file
DVDragana Vujic
Dragana Vujic
MSMarija Simić
Marija Simić
With the appearance of the first cases of COVID-19 infection, which had a severe clinical picture accompanied by respiratory insufficiency, as well as multiorgan dysfunction, mesenchymal stem cells became the subject of intensive research. The main cause of tissue and organ damage in patients with COVID-19 infection is thought to be a cytokine storm, which is the result of an imbalance in the regulation of the host immune system. Previous studies have shown that mesenchymal stem cells have an immunomodulatory effect and can prevent and reduce the cytokine storm triggered by the SARS-Cov-2 virus. Numerous clinical studies on the use of mesenchymal stem cells in patients with a severe clinical picture of COVID-19 are underway. Undoubtedly, cell therapy could be of great importance in the treatment of patients with a severe clinical picture of COVID-19, but it takes time to consider the efficacy and safety of such therapy, which is possible only through controlled multicenter clinical studies.